A Phase I/Ii, Open-Label Study Of Bbt-176, A Triple Mutation Targeting Egfr Tki, In Patients With Nsclc Who Progressed After Prior Egfr Tki TherapyS. M. Lim,D-W. Kim, J. E. Jung,G. Lee, J-H. Ryou, S-U. Kang,Y-H. Lee, H-J. Shin, S. Y. Yum, E. Yim,S-Y. Lee,J. S. AhnANNALS OF ONCOLOGY（2021）引用 8|浏览8暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
